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Abstract
Background: We conducted a genome-wide association study (GWAS) and validation study for
left ventricular (LV) mass in the Family Blood Pressure Program – HyperGEN population. LV mass
is a sensitive predictor of cardiovascular mortality and morbidity in all genders, races, and ages.
Polymorphisms of candidate genes in diverse pathways have been associated with LV mass.
However, subsequent studies have often failed to replicate these associations. Genome-wide
association studies have unprecedented power to identify potential genes with modest effects on
left LV mass. We describe here a GWAS for LV mass in Caucasians using the Affymetrix GeneChip
Human Mapping 100 k Set. Cases (N = 101) and controls (N = 101) were selected from extreme
tails of the LV mass index distribution from 906 individuals in the HyperGEN study. Eleven of 12
promising (Q < 0.8) single-nucleotide polymorphisms (SNPs) from the genome-wide study were
successfully genotyped using quantitative real time PCR in a validation study.
Results: Despite the relatively small sample, we identified 12 promising SNPs in the GWAS. Eleven
SNPs were successfully genotyped in the validation study of 704 Caucasians and 1467 African
Americans; 5 SNPs on chromosomes 5, 12, and 20 were significantly (P ≤ 0.05) associated with LV
mass after correction for multiple testing. One SNP (rs756529) is intragenic within KCNB1, which
is dephosphorylated by calcineurin, a previously reported candidate gene for LV hypertrophy
within this population.
Conclusion: These findings suggest KCNB1 may be involved in the development of LV hypertrophy
in humans.
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Background
Increased mass of the left ventricle (LV) is considered a
compensatory process which maintains cardiac output in
response to pathological stimuli such as hypertension,
obesity, and myocardial injury [1,2]. Left ventricular mass
is a sensitive predictor of cardiovascular mortality and
morbidity in all genders, races, and ages [3-6]. Evidence
suggests LV mass is, in part, under genetic control, with
heritability estimates generally falling between 0.17 and
0.59 [7-10]. The normal distribution of LV mass in popu-
lations suggests this phenotype is a complex trait influ-
enced by multiple genes. Some studies have reported
statistically significant association between LV mass and
the angiotensin converting enzyme gene (ACE) [11], gua-
nine nucleotide-binding protein gene (GNB3) [12], insu-
lin-like growth factor gene (IGF-1) [13], and neuropeptide
Y gene (NPY) [14], although other studies have failed to
provide evidence of association of LV mass with some of
these same genes (e.g., ACE [15], GNB3 [16]). Although
the dearth of consonant findings may be more indicative
of the nature of complex diseases than the quality of the
conflicting studies, candidate gene association studies are,
by definition, limited to investigating genes with previ-
ously known connections to the phenotype of interest.
Linkage studies have the advantage of scanning the entire
genome without such assumptions; however, they are
underpowered relative to association studies for com-
mon, complex genetic diseases [17]. Genome-wide associ-
ation studies (GWAS) offer both the exploratory benefits
of linkage and the statistical power of association.
We describe here a GWAS for LV mass in Caucasians using
the Affymetrix GeneChip Human Mapping 100 k Set fol-
lowed by a candidate SNP validation study. Cases and
controls were selected from the extremes of the LV mass
index distribution from 906 individuals in the Family
Blood Pressure Program (FBPP) – Hypertension Genetic
Epidemiology Network (HyperGEN) Study. The most sig-
nificant SNPs identified in the GWAS (i.e., those with the
smallest raw P  values) were examined in a validation
study of 704 Caucasians and 1467 African Americans. Five
SNPs on chromosomes 5, 12, and 20 were significantly
associated with LV mass in the validation study. One SNP
(rs756529) is intragenic within KCNB1, which is dephos-
phorylated by calcineurin, a previously reported candi-
date gene for LV hypertrophy within this population [18].
Methods
Study population
Study participants (101 cases, 101 controls for the GWAS;
2171 individuals for validation) were recruited from the
FBBP – HyperGEN Study [19]. HyperGEN is one of four
networks initiated and supported by the National Heart,
Lung and Blood Institute to identify genetic contributions
to hypertension. Subjects were drawn from population-
based cohorts (from the Atherosclerosis Risk in Commu-
nities Study in Minneapolis, MN and Forsyth County, NC;
the Minnesota Heart Survey; and the Utah Health Family
Tree Study), or from the community-at-large (Birming-
ham, AL). Recruitment criteria required that participating
sibships had ≥ 2 siblings who had been diagnosed with
hypertension before age 60. Hypertension was defined as
currently taking antihypertensive medication or having an
average systolic blood pressure ≥ 1 4 0  m m  H g  a n d / o r
diastolic blood pressure ≥ 90 mm Hg measured at two
separate clinic visits. Average blood pressure was calcu-
lated using the second and third measurements of three
readings using an oscillometric blood pressure monitor
(Dinamap 1846 SX/P; GE Healthcare, Waukesha, WI,
USA). Individuals with a history of type 1 diabetes or
severe renal disease were excluded. As this was a pilot
GWAS, we selected a modest number of cases and controls
from the Caucasian strata in a manner to maximize our
detection of association. Because we had observed linkage
evidence for the LV mass index (LVMI, defined as LV
mass/height2.7) phenotype (linkage data published sepa-
rately [20]) in the hypertension-affected sibships of the
HyperGEN population [21], we defined cases as subjects
in the extreme of the log-transformed (and roughly nor-
mal) LVMI distribution. Specifically, cases with the largest
LVMI values were selected in descending order from the
largest value. The reverse process was used to select con-
trols: individuals were selected from smallest LVMI values
in ascending order from the smallest value. Thus, cases
and controls were those above and below approximately
the 90th and 10th  percentile of the LVMI distribution,
respectively. The validation study samples consisted of all
remaining (i.e., after case-control selection) 704 Cauca-
sian siblings and all African American hypertensive sib-
lings (N = 1467) participating in the HyperGEN study. For
comparison purposes, a validation study association anal-
ysis was also conducted with the combined (i.e., the 202
individuals used as cases and controls plus the remaining
704 individuals, N = 906) Caucasian sample. About 85%
of the African Americans were recruited from geographi-
cally distant center (i.e., Birmingham, AL) from the Cau-
casian recruitment centers (e.g., Utah, Minnesota, and
North Carolina), and to that end, serve as a distinct pop-
ulation for the purposes of replication. This study was
approved by the centers' institutional review boards, and
all subjects gave informed consent.
Echocardiographic measures
Doppler, two-dimensional (2D), and M-mode (2D-
guided) echocardiograms were performed following a
standardized protocol previously described [22]. Certified
sonographers from each field center were trained at the
echocardiography reading center (New York Hospital-
Cornell Medical Center). M-mode and 2D echocardio-
grams via the parasternal acoustic window were recordedBMC Medical Genetics 2009, 10:43 http://www.biomedcentral.com/1471-2350/10/43
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for ≥ 10 beats. Measurements were made at the echocardi-
ography reading center using a computerized review sta-
tion equipped with a digitizing tablet and monitor
overlay used for calibration and quantification (Digison-
ics, Inc., Houston, TX, USA). LV linear dimensions were
measured by M-mode or 2D echocardiography according
to American Society of Echocardiography recommenda-
tions [23,24]. LV mass was calculated using end-diastolic
dimensions by an anatomically validated formula [25],
and indexed to height2.7 as described above. The repro-
ducibility of echocardiographic measures was assessed in
a substudy of 12 individuals who had echocardiograms
conducted two weeks apart.
Genotyping methods
The Affymetrix GeneChip Human Mapping 100 k Set,
consisting of two assays and two microarrays, was used for
the genome-wide scan. Methods were adapted from Mat-
suzaki et al. [26]. All genotyping results were analyzed
using the Affymetrix analysis software (GDAD and
GTYPE). Duplicate SNPs were typed on both chips in
order to detect potential sample mix-ups. For the valida-
tion study, SNPs found to be significant in the GWAS were
genotyped using the Applied Biosystems (ABI, Foster City,
CA, USA) TaqMan technology; probes were designed
using either Assay-on-Demand or Assay-by-Design.
Statistical and analytical methods
For the GWAS analysis, we first screened out monomor-
phic markers and markers that were not likely to be
informative as defined by minor allele frequency < 0.05.
A simple logistic model was used to analyze the associa-
tion of case-control status with each SNP separately. Since
some of the subjects were siblings (a total of 55 in cases
and controls), empirical standard error estimates were
used to correct for the within-family correlation using
generalized estimation equations (GEE) with exchangea-
ble working correlation matrix [27,28]. Because the
number of minor allele homozygotes in our sample
tended to be small (e.g., ~8 for a SNP with a minor allele
frequency of 20%), we chose to use a dominant model.
Adjusted P values were calculated using Holm's method
to control for family-wise error rate [29]. Q values [30]
were calculated using the qvalue package in R to allow
control of the false discovery rate. All analyses for the
GWAS were carried out using R http://www.r-project.org.
Eleven of the 12 chosen SNPs from the GWAS could be
successfully genotyped for the two ethnic groups in the
validation study. For the validation study SNPs, tests of
genotype distribution for Hardy-Weinberg equilibrium
were conducted in each race group by an exact test imple-
mented in the computer program Pedstats [31]. HWE was
examined in all individuals and a set of unrelated individ-
uals (876 African Americans and 545 Caucasians) that
were selected by an algorithm implemented in Pedstats.
Since multiple SNPs were tested, P < 0.01 was considered
to be statistically significant for violation of HWE.
Two phenotypes were examined in the validation study,
the continuous variable of LVMI and the categorical phe-
notype of left ventricular hypertrophy (LVH) defined as
LVMI > 47 g/m2.7 in women or > 50 g/m2.7 in men. We
used GEE with an exchangeable working correlation
matrix for within-family correlation to test the association
between the validation study SNPs and continuous and
categorical LV phenotypes [27,28]. Covariates that were
adjusted for included age, sex, weight, systolic blood pres-
sure, and diabetes. For each SNP, genotypes were grouped
into two categories in the same manner as in the GWAS
analysis. Natural log-transformation was performed for
LVMI to normalize the trait distribution. As noted above,
for Caucasians we also analyzed the GWAS and validation
study participants in a combined analysis.
Results
In the echocardiographic reproducibility substudy, the
intraclass correlation coefficient was 0.90. In another
study using methods comparable to those of HyperGEN,
the echocardiography reading center at Cornell reported
good reproducibility of LV mass (ri = 0.93) [32]. All
Affymetrix GeneChips passed the standard cut-off for the
genotype call rate (< 85%). Approximately 8% of the
SNPs on the gene chip set were monomorphic in our sam-
ple; another ~10% had minor allele frequencies less than
5%, leaving 96,258 informative SNPs in our genome-wide
scan.
In the GWAS, both the case and control samples had
mean ages of about 60 years and women comprised about
66% of both groups. The case group had a significantly
higher mean body mass index, systolic blood pressure,
pulse pressure, and, by design, LVMI. Mean LVMI in cases
was 56.2 ± 6.3 g/m2.7; in controls mean LVMI was 31.4 ±
3.9 g/m2.7. Other demographic and clinical characteristics
of cases and controls are shown in Table 1.
We identified the 12 SNPs from the genome-wide analysis
with the smallest raw P values to genotype in the subse-
quent validation study. The 12 SNPs all had unadjusted P
values < 0.0001 and all had Q values < 0.8 [30]. The esti-
mated positive false discovery rate was 75% [30,33]. The
next best SNP (i.e., the SNP with the 13th lowest raw P
value) had a Q value of 1.00. The SNP with the strongest
association in the genome-wide analysis (rs409045 on
chromosome 5p13.2) had an adjusted P  = 0.08 using
Holm's method [29]. Table 2 lists unadjusted P values for
the 12 top-ranked SNPs from the genome-wide scan.BMC Medical Genetics 2009, 10:43 http://www.biomedcentral.com/1471-2350/10/43
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Demographic and clinical characteristics of the validation
study samples are shown in Table 1. In African Americans,
only one SNP (rs6961069) was not at HWE at P < 0.01. In
Caucasians, no significant departures from HWE were
detected for SNPs in the set of unrelated individuals. In
the Caucasian replication sample, all but one of the SNPs
identified by GWAS (rs756529) had minor alleles that
were the same as those in the GWAS sample. In the Afri-
can American validation study sample, six SNPs had dif-
ferent minor alleles than those in the Caucasian GWAS
sample: rs6961069, rs10499859, rs756529, rs10483186,
rs6450415, and rs4129418. Tables 3, 4, and 5 present the
P values for the 11 successfully genotyped SNPs for the
704 Caucasians not used in the case-control GWAS, for
the combined 906 Caucasian sample (i.e., 202 cases and
controls plus 704 remaining Caucasians), and for the
1467 African Americans. Effect sizes, as geometric means,
for significant associations (P  < 0.05) with LVMI are
shown in Figure 1. The effect sizes, as odds ratios, for the
two significant (P < 0.05) associations with LVH were 1.60
(1.01, 2.52, 95% confidence interval) for rs4129218 in
Caucasians and 1.40 (1.03, 1.92, 95% confidence inter-
val) for rs756529 in African Americans.
Discussion
Using a GWAS and validation study design, we identified
novel SNPs associated with increased LV mass, a pheno-
type with strong attributable risk for cardiovascular mor-
tality and morbidity. We identified 12 SNPs from the
GWAS conducted among cases and controls. The high
false discovery rate (i.e., 75% of our SNPs were likely false
positives) resulting from our limited sample size in the
GWAS was acceptable, as this stage of the research was
intended to capture the best pool of signals that could
subsequently be tested in the validation study. In the val-
idation study, we were able to successfully genotype 11 of
Table 1: Demographic and clinical characteristics by case-control status and validation study population.
Genome-wide association Validation study
Characteristics Case
(N = 101)
Control
(N = 101)
P* Caucasians (N = 704) African Americans
(N = 1467)
Age, years 59.1 ± 9.1 60.3 ± 9.3 0.34 60.7 ± 8.34 50.8 ± 11.0
Females, % 66.3 66.3 1.00 48.9 64.4
Diabetic, % 19.8 12.9 0.18 15.8 22.8
Weight, kg† 90.1 (70.9 – 114.4) 79.6 (64.2 – 98.7) 0.0001 85.5 ± 17.8 89.9 ± 21.5
Height, cm 164.6 ± 8.0 169.0 ± 8.7 0.0002 168.9 ± 9.1 167.3 ± 9.1
Body mass index, kg/m2† 33.4 (26.7 – 41.8) 27.9 (23.3 – 33.5) < 0.0001 29.9 ± 5.5 32.2 ± 7.5
Percentage of body fat‡ 39.3 ± 8.9 36.0 ± 8.2 0.012 35.3 ± 8.6 39.9 ± 9.5
Systolic blood pressure, mm Hg 135.5 ± 20.8 126.1 ± 15.7 0.0003 126.8 ± 20.2 132.1 ± 22.5
Diastolic blood pressure, mm Hg 70.9 ± 12.5 71.0 ± 10.2 0.90 70.1 ± 10.6 75.2 ± 11.7
Pulse pressure, mm Hg 64.7 ± 16.2 55.1 ± 13.7 < 0.0001 56.7 ± 16.2 56.9 ± 16.7
Postural SBP change, mm Hg -1.32 ± 14.7 -0.91 ± 15.0 0.85 -2.55 ± 14.8 1.63 ± 14.2
Hypertension status
Normal BP, % 0.0 0.0 - 22.9 13.5
Mild hypertension, % 42.6 57.4 - 35.2 37.4
Severe hypertension, % 57.4 42.6 - 41.9 49.1
Antihypertensive drugs, N 1.43 ± 0.84 1.35 ± 0.71 0.42 1.38 ± 0.80 1.35 ± 0.92
LV mass, g 214.5 ± 32.8 130.3 ± 21.8 < 0.0001 171.7 ± 40.5 178.1 ± 49.8
LV mass/body surface area, g/m2 108.9 ± 15.0 68.0 ± 9.0 < 0.0001 87.6 ± 17.3 89.9 ± 22.7
LV mass/height2.7, g/m2.7 56.2 ± 6.3 31.4 ± 3.9 < 0.0001 41.6 ± 8.66 44.4 ± 12.1
Urinary albumin:creatinine ratio† 6.87 (1.93 – 24.4) 3.11 (0.58 – 16.6) 0.0002 3.74 (0.92 – 15.2) 7.24 (1.27 – 41.3)
*P for comparison of means between cases and controls; †Reported as geometric mean (SD range) because natural-log transformed values were 
compared between cases and controls; ‡Lukaski equation; SBP = systolic blood pressure
Table 2: SNPs from the genome-wide scan with Q values < 0.8 
(i.e., false-discovery rate < 80%).
SNP Chr Position* MAF P†
rs409045 5 34664384 0.44 8.47E-07
rs6450415 5 56384642 0.56 6.43E-05
rs1833534 5 162753563 0.19 9.62E-05
rs6961069 7 80056897 0.57 7.34E-05
rs10499859 7 80096746 0.69 3.27E-06
rs4129000 12 64239801 0.28 2.26E-05
rs4129218 12 64244928 0.38 5.19E-05
rs1155635 13 69845453 0.60 9.09E-05
rs2415872 14 44177211 0.72 8.68E-05
rs238688 20 3473701 0.33 8.33E-05
rs756529 20 47444415 0.68 9.10E-05
rs10483186 22 33669852 0.69 3.12E-05
*dbSNP positions are as bases, from NCBI Build 36; †unadjusted P 
value; Chr = chromosome; MAF = Overall frequency of carriers of 
minor allele (homozygotes + heterozygotes); SNP = single-nucleotide 
polymorphismBMC Medical Genetics 2009, 10:43 http://www.biomedcentral.com/1471-2350/10/43
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these 12 SNPs in the remaining members of the Hyper-
GEN sample. Among 704 Caucasian participants, 3 of the
11 SNPs were associated with our phenotypes (rs409045,
rs4129000, rs4129218). Among 1467 African American
HyperGEN participants in the phase two sample, we
found modest associations for two of the 11 SNPs
(rs238688 and rs756529, chromosome 20).
Of the 11 SNPs that were moved forward to the validation
study, two (rs238688 and rs756529, chromosome 20)
were intragenic (see Tables 3, 4, and 5). The former is
located in the attractin gene (ATRN), also known as the
mahogany gene because of its role in determining coat
color in mice. ATRN is involved in diet regulation of obes-
ity in mice and may be relevant for human obesity. This
may be important in the current context because body
weight is the strongest predictor of LV mass among all fac-
tors measured in the HyperGEN study. However, we did
not find an association between this SNP and body
weight, body mass index, or waist size in HyperGEN. In
addition to its potential effects on LV mass and body size,
ATRN function parallels that of proteoglycan receptors
that are responsible for regulating cell interactions during
inflammatory reactions. Either of these mechanisms
(energy metabolism and/or inflammation) could be
important pathways for the development of LV hypertro-
phy. The second chromosome 20 SNP, rs756529, lies
within the potassium voltage-gated channel, Shab-related
subfamily, member 1 gene (KCNB1). This gene is particu-
larly interesting because its protein product is dephospho-
rylated by calcineurin. Calcineurin, in both animal and
human studies, is associated with LV hypertrophy [18],
and this may reflect a unique mechanism for develop-
ment of LV hypertrophy in hypertension. We have previ-
ously shown a strong association between genetic variants
in the promoter region of this gene and LV mass in this
same population [18].
GWAS genotyping was done only in Caucasians, although
in the validation study both the Caucasian and African
American families within HyperGEN were genotyped. We
observed different association results in Caucasians and
African Americans. This lack of a consistent finding
between ethnic groups is not unexpected since the allele
frequencies were quite different between the two ethnic
groups for many of the SNPs, and allele frequencies
impact the power to detect association. Many risk factors
for LV hypertrophy, including weight and hypertension,
also differ between the groups. If the genetic effect esti-
mated by the SNP is influenced by these risk factors, then
the association observed would also be different in Cauca-
sians and African Americans.
We compared our findings to Vasan et al.'s GWAS that
genotyped 1345 participants from the Framingham Heart
Study using the same 100 k GeneChip [34]. Although
none of the 12 most promising SNPs from the GWAS were
among the top SNPs associated with echocardiographic
traits in Vasan et al., two of their most significant SNPs
(rs580859 associated with LV diastolic dimension,
rs26438 associated with aortic root diameter) were
located within 2 Mb of SNPs in our top 12 (rs1833534,
rs1155635). Future work within HyperGEN will explore
these regions more extensively.
The relatively small sizes of our case and control groups
may have been seen – a priori – as a limitation of this
study. Although it is likely that we missed a number of
interesting genetic associations of smaller magnitude, the
findings we do have were statistically significant in the
validation study. Therefore, a posteriori concerns about
power are largely academic. In general, small sample sizes
are a concern because they increase the chances of false
negative findings (i.e., increased Type 2 errors). The
extreme degree of multiple testing inherent in GWAS (and
the commensurate increase in the harvest of false posi-
tives) is explicitly addressed by the GWAS-validation
study design. Indeed, five of the 11 SNPs identified during
the GWAS were significant in the validation, suggesting
that 55% (i.e., 100% minus 45%), were false positive
findings, which is much less than predicted by our FDR
method calculation (i.e., 75%).
Another limitation of this study is the relative lack of
whole-genome coverage afforded by the Affymetrix Gene-
Chip Human Mapping 100 k Set, especially when viewed
Effect sizes (geometric means) of significant (P < 0.05) left  ventricular mass index associations in the validation study for  Caucasians and African Americans Figure 1
Effect sizes (geometric means) of significant (P < 
0.05) left ventricular mass index associations in the 
validation study for Caucasians and African Ameri-
cans. Error bars indicate 95% confidence intervals.BMC Medical Genetics 2009, 10:43 http://www.biomedcentral.com/1471-2350/10/43
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in the context of more recently developed chips that offer
significantly greater coverage. Although it is therefore true
that our findings are far from comprehensive, the rela-
tively small net cast by the 100 k chip does not diminish
the relevance of the significant associations that we found.
An additional concern could also be potential population
stratification; however, this is minimized by the family
design of our study. We also examined the potential for
population structure using a principle components analy-
sis. We identified 6 principle components from the GWAS
data; however, adjustment for these did not materially
change the results (data not presented).
Although using a sample comprised of only the center of
the LVMI distribution for the validation study admits
some spectrum bias, this design offers a number of dis-
tinct advantages. For example, by evaluating the impor-
tance of the SNPs in the middle percentiles of the LVMI
Table 3: Results (as P values) from the validation study genotyping and association analyses for the Caucasian sample, not including 
GWAS cases and controls.*
GWAS Cases and Controls (101 pairs) Caucasians (N = 704)
(No GWAS cases & controls)
SNP Chr P Log(LVMI) LVH MAF Nearest
object
Distance (Mb)
rs409045 5p13.3 8.47E-07 0.0101 0.0798 0.39 RAI14 0.028
rs6450415 5q11.2 6.43E-05 0.51 0.98 0.45 FLJ35954 0.10
rs1833534 5q34 9.62E-05 0.49 0.54 0.12 CCNG1 0.044
rs6961069 7q21 7.34E-05 0.97 0.38 0.41 SEMA3C 0.040
rs10499859 7q21 3.27E-06 0.65 0.22 0.45 CD36 0.15
rs4129000 12q14.3 2.26E-05 0.035 0.18 0.16 LOC729298 0.095
rs4129218 12q13.3 5.19E-05 0.007 0.038 0.21 LOC729298 0.10
rs1155635 13q21.33 9.09E-05 0.92 0.57 0.39 KLHL1 0.27
rs238688 20p13 8.33E-05 0.31 0.59 0.27 ATRN Intron
rs756529 20q13.13 9.10E-05 0.74 0.32 0.41 KCNB1 Intron
rs10483186 22q12 3.12E-05 0.55 0.086 0.46 LOC91464 0.12
*Analysis adjusted for age, sex, weight, systolic blood pressure, and diabetes; Chr = chromosome; GWAS = genome-wide association study; LVMI 
= left ventricular mass index defined as LV mass/height2.7; LVH = left ventricular hypertrophy defined as LVMI > 47 g/m2.7 in women and > 50 g/m2.7 
in men; MAF = Overall frequency of carriers of minor allele (homozygotes + heterozygotes); SNP = single-nucleotide polymorphism
Table 4: Results (as P values) from the validation study genotyping and association analyses for the Caucasian sample, including GWAS 
cases and controls.*
GWAS Cases and Controls (101 pairs) Caucasians (N = 906)
(With GWAS cases & controls)
SNP Chr P Log(LVMI) LVH MAF Nearest
Object
Distance (Mb)
rs409045 5p13.3 8.47E-07 0.0015 0.0006 0.38 RAI14 0.028
rs6450415 5q11.2 6.43E-05 0.075 0.068 0.45 FLJ35954 0.10
rs1833534 5q34 9.62E-05 0.0063 0.0118 0.13 CCNG1 0.044
rs6961069 7q21 7.34E-05 0.062 0.56 0.41 SEMA3C 0.040
rs10499859 7q21 3.27E-06 0.091 0.56 0.45 CD36 0.15
rs4129000 12q14.3 2.26E-05 < 0.0001 0.0002 0.16 LOC729298 0.095
rs4129218 12q13.3 5.19E-05 < 0.0001 0.0001 0.21 LOC729298 0.10
rs1155635 13q21.33 9.09E-05 0.024 0.0041 0.38 KLHL1 0.27
rs238688 20p13 8.33E-05 0.56 0.66 0.27 ATRN Intron
rs756529 20q13.13 9.10E-05 0.36 0.18 0.41 KCNB1 Intron
rs10483186 22q12 3.12E-05 0.065 0.38 0.46 LOC91464 0.12
*Analysis adjusted for age, sex, weight, systolic blood pressure, and diabetes; Chr = chromosome; GWAS = genome-wide association study; LVMI 
= left ventricular mass index defined as LV mass/height2.7; LVH = left ventricular hypertrophy defined as LVMI > 47 g/m2.7 in women and > 50 g/m2.7 
in men; MAF = Overall frequency of carriers of minor allele (homozygotes + heterozygotes); SNP = single-nucleotide polymorphismBMC Medical Genetics 2009, 10:43 http://www.biomedcentral.com/1471-2350/10/43
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distribution, we might better assess the relevance of the
variants for the overall hypertensive population. Because
our validation study made use of samples from the same
source cohort the GWAS cases and controls were drawn
from, we eliminate population stratification as a possible
explanation of findings. Finally, the phenotypes used in
both the GWAS and validation study were collected by the
same technicians and read by the same readers, thereby
reducing measurement bias as an explanation for any lack
of consistent findings.
Conclusion
In summary, we found suggestive evidence of novel SNPs
associated with LV hypertrophy on chromosomes 5 and
12 in Caucasians, and chromosome 20 in African Ameri-
cans. Future work will characterize these regions with a
greater number of SNPs in order to further confirm the
genomic regions as true positives and to identify the puta-
tive genetic variant and its functional relevance with
respect of LV hypertrophy.
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